85.04
Overview
News
Price History
Option Chain
Why AZN Down?
Discussions
Forecast
Stock Split
Dividend History
Astrazeneca PLC stock is traded at $85.04, with a volume of 9.09M.
It is down -0.40% in the last 24 hours and up +4.70% over the past month.
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases. The company's marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Eklira Genuair/Tudorza Pressair, Fasenra, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, Symbicort Turbuhaler, and Tudorza Pressair for respiratory diseases; Fluenz FluMist/Tetra Quadrivalen and Synagis3 for infection diseases; Movantik/Moventig, Seroquel IR, Seroquel XR, and Vimovo4 for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases. The company serves primary care and specialty care physicians through distributors and local representative offices. AstraZeneca PLC has a strategic partnership with Bicycle Therapeutics; and with Biothera Pharmaceuticals, Inc. to evaluate cancer related drugs, as well as has a collaboration agreement with Innate Pharma S.A. for oncology development. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC has clinical collaboration with Immunomedics, Inc. for the development of Imfinzi(R) and sacituzumab govitecan combination therapy, to include second-line metastatic non-small cell lung cancer. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom.
See More
Previous Close:
$85.38
Open:
$85.9
24h Volume:
9.09M
Relative Volume:
1.94
Market Cap:
$263.74B
Revenue:
$56.53B
Net Income/Loss:
$8.32B
P/E Ratio:
31.94
EPS:
2.6622
Net Cash Flow:
$8.49B
1W Performance:
+1.66%
1M Performance:
+4.70%
6M Performance:
+27.38%
1Y Performance:
+9.72%
Astrazeneca PLC Stock (AZN) Company Profile
Name
Astrazeneca PLC
Sector
Industry
Phone
44 20 3749 5000
Address
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge
Compare AZN with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
AZN
Astrazeneca PLC
|
85.04 | 264.72B | 56.53B | 8.32B | 8.49B | 2.6622 |
Astrazeneca PLC Stock (AZN) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Apr-15-25 | Initiated | Exane BNP Paribas | Outperform |
Feb-13-25 | Upgrade | UBS | Neutral → Buy |
Feb-12-25 | Initiated | Morgan Stanley | Overweight |
Nov-20-24 | Upgrade | UBS | Sell → Neutral |
Nov-06-24 | Upgrade | Deutsche Bank | Sell → Hold |
Sep-13-24 | Downgrade | Deutsche Bank | Hold → Sell |
May-30-24 | Initiated | Goldman | Buy |
Apr-16-24 | Upgrade | Deutsche Bank | Sell → Hold |
Feb-08-24 | Downgrade | Deutsche Bank | Hold → Sell |
Jan-23-24 | Initiated | Morgan Stanley | Overweight |
Jan-16-24 | Resumed | UBS | Sell |
Jan-03-24 | Downgrade | Jefferies | Buy → Hold |
Dec-18-23 | Initiated | HSBC Securities | Buy |
Sep-25-23 | Upgrade | Jefferies | Hold → Buy |
Jul-14-23 | Initiated | HSBC Securities | Buy |
Jul-12-23 | Upgrade | UBS | Neutral → Buy |
Jul-05-23 | Downgrade | Deutsche Bank | Buy → Hold |
Apr-11-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Jan-05-23 | Initiated | BMO Capital Markets | Outperform |
Sep-15-22 | Downgrade | Credit Suisse | Outperform → Neutral |
Sep-07-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Aug-29-22 | Upgrade | Argus | Hold → Buy |
Jun-14-22 | Downgrade | UBS | Buy → Neutral |
Feb-11-22 | Upgrade | DZ Bank | Sell → Hold |
Dec-07-21 | Downgrade | Jefferies | Buy → Hold |
Aug-12-21 | Resumed | JP Morgan | Overweight |
Apr-12-21 | Downgrade | Argus | Buy → Hold |
Mar-16-21 | Upgrade | Jefferies | Hold → Buy |
Feb-25-21 | Upgrade | UBS | Neutral → Buy |
Jan-15-21 | Initiated | Deutsche Bank | Buy |
Dec-07-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Nov-30-20 | Upgrade | UBS | Sell → Neutral |
Nov-11-20 | Upgrade | HSBC Securities | Reduce → Hold |
Sep-29-20 | Initiated | Berenberg | Buy |
Nov-22-19 | Initiated | SVB Leerink | Outperform |
Oct-25-19 | Upgrade | Liberum | Hold → Buy |
Apr-02-19 | Downgrade | UBS | Neutral → Sell |
Feb-05-19 | Initiated | Exane BNP Paribas | Outperform |
Jan-25-19 | Upgrade | Shore Capital | Hold → Buy |
Dec-11-18 | Resumed | Jefferies | Hold |
Oct-09-18 | Initiated | Guggenheim | Buy |
Aug-16-18 | Downgrade | Jefferies | Buy → Hold |
Mar-19-18 | Upgrade | Jefferies | Hold → Buy |
Feb-06-18 | Reiterated | Leerink Partners | Mkt Perform |
Feb-05-18 | Reiterated | Bernstein | Outperform |
Jan-18-18 | Reiterated | Leerink Partners | Mkt Perform |
Dec-29-17 | Upgrade | JP Morgan | Neutral → Overweight |
Oct-16-17 | Upgrade | Credit Suisse | Neutral → Outperform |
Sep-25-17 | Upgrade | Exane BNP Paribas | Neutral → Outperform |
Sep-22-17 | Upgrade | Bernstein | Mkt Perform → Outperform |
View All
Astrazeneca PLC Stock (AZN) Latest News
AstraZeneca boosts investment in Virginia plant (AZN:NASDAQ) - Seeking Alpha
AstraZeneca to invest $4.5 billion in Virginia manufacturing facility By Investing.com - Investing.com South Africa
AstraZeneca to invest $4.5B in Virginia facility - breakingthenews.net
AstraZeneca ups investment at new Virginia facility to USD4.5 billion - MarketScreener
AstraZeneca (AZN) Invests $4.5B in New Virginia Facility to Boos - GuruFocus
AstraZeneca to increase investment & scope of Virginia manufacturing facility to $4.5 bln - MarketScreener
AstraZeneca breaks ground at $4.5 billion Virginia plant as drugmakers court Trump - MarketScreener
3,600 Jobs: AstraZeneca Expands Virginia Investment to $4.5B, Adds ADC Cancer Manufacturing - Stock Titan
Turbine Launches Collaboration with Astrazeneca, Leveraging Turbine's Virtual Disease Models to Rationalize ADC Discovery - MarketScreener
What machine learning models say about AstraZeneca PLC Depositary ReceiptWeekly Market Outlook & High Accuracy Buy Signal Tips - newser.com
AstraZeneca (AZN) Unaffected by Potential Tariffs on Generic Dru - GuruFocus
Volume spikes in AstraZeneca PLC Depositary Receipt stock – what they meanWeekly Stock Recap & Real-Time Market Sentiment Alerts - newser.com
Algen inks $555m AstraZeneca partnership for AI-powered drug discovery - BioXconomy
Turbine Launches Collaboration with AstraZeneca, Leveraging Turbine's Virtual Disease Models to Rationalize ADC Discovery - MarketScreener
Advanced analytics toolkit walkthrough for AstraZeneca PLC Depositary Receipt2025 Price Action Summary & AI Driven Price Forecasts - newser.com
Will AstraZeneca PLC Depositary Receipt bounce back from current supportEarnings Risk Report & High Yield Stock Recommendations - newser.com
AstraZeneca PLC $AZN Shares Sold by Prime Capital Investment Advisors LLC - MarketBeat
AstraZeneca PLC (AZN)’s Datroway Wins FDA Nod for Lung Cancer Breakthrough - MSN
AstraZeneca PLC Depositary Receipt recovery potential after sell off2025 Price Action Summary & Verified Momentum Stock Ideas - newser.com
AstraZeneca PLC Depositary Receipt stock momentum explained2025 Performance Recap & Step-by-Step Swing Trade Plans - newser.com
Stock of the Week: Is AstraZeneca a Buy After Share Price Jump? - Morningstar Canada
Barclays Keeps AstraZeneca at Overweight, Expects 'Resilient' Q3 Results - MarketScreener
AstraZeneca's Baxdrostat Meets Goal in Resistant Hypertension Study - Yahoo Finance
What AstraZeneca Can Teach Us About Scaling Innovation Through Ecosystem Collaboration - MarketScreener
AstraZeneca Shares Surge 14% as Investment Pause Spurs Fresh Valuation Debate - Yahoo
Thermo Fisher's New R&D Alliance With AstraZeneca May Lift Its Stock - sharewise.com
AstraZeneca's Baxdrostat Shows Meaningful Blood Pressure Control In Patients With Resistant Hypertension - Benzinga
Another Baxdrostat Success Takes Pressure Off AstraZeneca - insights.citeline.com
AstraZeneca PLC Announces Baxdrostat Met Primary Endpoints in Bax24 Phase Iii Trial in Patients with Resistant Hypertension - MarketScreener
AstraZeneca (LSE:AZN): Exploring Valuation as Shares Move Steadily Higher - Yahoo Finance
AstraZeneca PLC $AZN Stock Holdings Lowered by Meitav Investment House Ltd. - MarketBeat
AstraZeneca (AZN) Reports Success in Phase 3 Hypertension Trial - GuruFocus
AstraZeneca Reports Positive Bax24 Trial Results for Hypertension - AskTraders.com
AstraZeneca Says Phase 3 Trial of Baxdrostat Meets Endpoint in Resistant Hypertension - MarketScreener
AstraZeneca Upgraded, Home Depot Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
AstraZeneca reports Phase III trial success for baxdrostat in hypertension - Investing.com
AstraZeneca PLC Announces Baxdrostat Demonstrates A Statistically Significant and Highly clinically meaningful Reduction in 24-Hour Systolic Blood Pressure Compared with Placebo - MarketScreener
AstraZeneca drug baxdrostat cuts blood pressure in key late-stage trial - MarketScreener
AstraZeneca and Daiichi’s Datroway trumps chemo in first-line breast cancer - clinicaltrialsarena.com
D.B. Root & Company LLC Cuts Stake in AstraZeneca PLC $AZN - MarketBeat
BreakingviewsAstraZeneca’s New York shift augurs London exodus - Reuters
AstraZeneca blood pressure drug succeeds in late-stage trial - Financial Times
AstraZeneka presents results for patients with resistant hypertension - MarketScreener
AstraZeneca’s experimental hypertension drug shows promising results - Investing.com
AstraZeneca’s baxdrostat hits key goal in major blood pressure trial - Proactive financial news
AstraZeneca says baxdrostat met primary endpoint in BAX24 Ph3 trial - MarketScreener
AstraZeneca : Baxdrostat met primary endpoint in Bax24 Ph3 trial - MarketScreener
REGAstraZeneca PLCBaxdrostat met primary endpoint in Bax24 Ph3 trial - TradingView
AstraZeneca Taps Gene Editing And AI Platform For Drug Discovery For Immunology Diseases - Benzinga
AstraZeneca (AZN) Achieves Key Milestones in Breast Cancer Treat - GuruFocus
AstraZeneca, Daiichi Sankyo succeed in late-stage breast cancer study - Seeking Alpha
Astrazeneca PLC Stock (AZN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):